Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0SEBGP
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
ENDOS/ADC
|
|||||
| Synonyms |
ENDOS-ADC; ENDOS ADC; ENDOSADC
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 3 Indication(s)
Ewing sarcoma [ICD11:2B52]
Investigative
Melanoma [ICD11:2C30]
Investigative
Neuroblastoma [ICD11:2A00]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.5-4
|
|||||
| Antibody Name |
Anti-CD248 mAb hMP-E-8.3
|
Antibody Info | ||||
| Antigen Name |
Endosialin (CD248)
|
Antigen Info | ||||
| Payload Name |
Duocarmycin derivative
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Val-Cit
|
Linker Info | ||||
| Conjugate Type |
Partial reduce the antibody and conjugate the drug to the available reduced interchain cysteine residues.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.